Gastrointestinal Cancer

Neoadjuvant Nivolumab-Ipilimumab Could Be New Standard Care in dMMR Colon Cancer

By

Vicki Moore, PhD

Publish Date September 27, 2022

Neoadjuvant nivolumab and ipilimumab produced an “unprecedented” major pathologic response rate in the NICHE-2 study, according to the lead study author.

Fruquintinib Potentially Practice-Changing in Refractory Metastatic Colorectal Cancer

By

Jessica Nye, PhD

Publish Date September 23, 2022

Adding fruquintinib to best supportive care improved progression-free survival and overall survival in the FRESCO-2 trial.

Risks of Second Primary Malignancies Increased in Colorectal Cancer Survivors

By

Vicki Moore, PhD

Publish Date September 16, 2022

A systematic review and meta-analysis sought to determine the risk of secondary primary cancer for survivors of colorectal cancer.

Results of Pancreatic Cancer Trials Are Not Being Published

By

Vicki Moore, PhD

Publish Date September 13, 2022

Researchers found that 30% of pancreatic adenocarcinoma trials completed from 2010 through 2020 did not have results available.

Chemotherapy Doublets Remain Standard Care for Advanced Digestive Neuroendocrine Carcinoma

By

Leah Lawrence

Publish Date September 9, 2022

Etoposide plus cisplatin and irinotecan plus cisplatin remain the standard first-line chemotherapy options for advanced digestive neuroendocrine carcinoma, according to researchers.